The Europeans Medicines Agency has confirmed that it is working with international regulatory bodies to monitor the possible risk of radioactive contamination of medicines manufactured in Japan following the radiation leak from the Fukushima Nuclear Power Plant.
The Japanese authorities combined with other regulatory partners around the world have reassured the European Medicines Agency that the risk to public and animal health is very small. The EMA is taking a precautionary approach that takes into account the measures put in place in the European Union for food and animal feed. Marketing authorisation holders are responsible for insuring the continued quality and safety of medicines. Medicines manufactured in the areas closest to the power plant have been asked to test their products to determine the level of radioactive material prior to export from Japan. From the information received from Japanese companies to date only a small number of medicines are manufactured in these areas and are therefore potentially effected.
